A RANDOMIZED TRIAL COMPARING THE EFFICACY AND SAFETY OF INTRAVITREAL TRIAMCINOLONE WITH OBSERVATION TO TREAT VISION LOSS ASSOCIATED WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION THE STANDARD CARE VERSUS CORTICOSTEROID FOR RETINAL VEIN OCCLUSION (SCORE) STUDY REPORT 5

摘要

Research Objective To determine whether the intravitreal triamcinolone at doses of 1 or 4 mg produces greater visual benefit than observation for the treatment of vision loss associated with macular edema secondary to central retinal vein occlusion (CRVO), and to evaluate the efficacy and safety of the 1-mg and 4-mg triamcinolone doses. Study Design Multicenter, prospective, randomized clinical trial. Location Multiple clinical sites within the United States. Funding Source National Eye Institute and in part by Allergan Inc.